Underestimated Value of Sarcopenia in Gastric Cancer Surgery
Literature reviews
Martynas Lukšta
Vilnius University, Lithuania
Raminta Lukšaitė-Lukštė
Vilnius University, Lithuania
Augustinas Baušys
Vilnius University, Lithuania
Kęstutis Strupas
Vilnius University, Lithuania
Published 2020-06-10
https://doi.org/10.15388/LietChirur.2020.19.20
PDF
HTML

Keywords

sarcopenia
surgical oncology
gastric cancer

How to Cite

1.
Lukšta M, Lukšaitė-Lukštė R, Baušys A, Strupas K. Underestimated Value of Sarcopenia in Gastric Cancer Surgery. LS [Internet]. 2020Jun.10 [cited 2022Dec.4];19(1-2):12-9. Available from: https://www.journals.vu.lt/lietuvos-chirurgija/article/view/18363

Abstract

Surgery remains the only potentially curative option for gastric cancer, although it is related to high postoperative morbidity and mortality rate. Approximately every second gastric cancer patient is diagnosed with sarcopenia, which is a significant risk factor for postoperative complications and poor long-term outcomes. However, sarcopenia is underestimated in routine clinical practice, since it remains the interest of clinical trials. Sarcopenia diagnostic criteria are not fully standardized, but it consists of tests for muscle strength, quantity and quality. They include grip strength, chair stand test, computed tomography, magnetic resonance imaging, ultrasound, bioelectrical impedance analysis and densitometry tests. Regarding the growing evidence for sarcopenia impact on surgical gastric cancer treatment results, it is a high probability that sarcopenia assessment will come to routine clinical practice. Although, until then there is a need for further clinical trials to standardize the diagnostic and to find effective treatment strategies.

PDF
HTML
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Please read the Copyright Notice in Journal Policy

Most read articles by the same author(s)